Mechanisms of Auto-immune Encephalitis

NCT02905136 | Completed

• 1 other identifier: 69HCL14_0439
• Study Type: observational
• Target: 253
• Locations: 1 country
• Sites: 1

Brief Summary

Neurological and psychiatric diseases are one of the major health problems worldwide. Decades of fundamental and clinical research have led to the model that these disorders results from synaptic imbalance between excitatory, inhibitory and modulatory systems in key brain structures. Although the network and neurotransmitter systems involved have been delineated, the mechanisms leading to improper neurotransmissions remain poorly understood. One major limitation lays in the difficulty to transpose the identified dysregulation in humans to relevant animal models in which molecular and cellular targets can be manipulated. The amino-acid glutamate mediates the vast majority of excitatory neurotransmission in the mammalian brain. We know that the glutamatergic synapses can change their strength by regulating surface expression and dynamics of their postsynaptic receptors, through changes in receptor recycling and/or lateral diffusion. This synaptic plasticity underlies higher cognitive functions such as learning and memory and is likely compromised in several disease states. Regulating glutamate receptor number and function is thus of primary importance. New subcellular imaging technique rendered possible the study of receptor trafficking and receptor regulation in various conditions including pathological models opening new fundamental questions. Moreover, recent breakthroughs on glutamate receptor structure offer unprecedented clues on the molecular and structural mechanisms underpinning receptor dysfunction at the atomic level. Recently, description of encephalitis associated with specific autoantibodies (Abs) directed against neuronal synaptic receptors or proteins (NSA-Abs) opens new lights in the pathophysiological mechanisms of some human brain disorders. The best example and the most frequent syndrome is the synaptic autoimmune encephalitis associated with autoantibodies against extracellular domains of the glutamatergic NMDA receptor (NMDAR-Abs). Classically, patients first present psychiatric symptoms with hallucinations and bizarre behavior before development of neurological symptoms such as seizures, dyskinesia, and autonomic instability. Despite the severity of neuropsychiatric symptoms, more than 80% of patients fully recover after immunomodulatory treatments and many arguments suggest a direct role of NMDAR-Abs in the symptoms. The investigators recently demonstrated that NMDAR-Abs directly modify, at the synaptic level, NMDAR lateral diffusion by disruption of the interaction between NMDAR and EphrinB2 receptor, a synaptic protein anchoring NMDAR at the synapse (Mikasova et al, Brain 2012; Dupuis et al, EMBOJ 2014). These data suggest that NMDAR-Abs could directly participate in the neuropsychiatric disorders observed in patients and that NMDAR dysfunctions could be directly responsible for the observed symptoms. Furthermore, these data suggest that other NSA-Abs directed against other synaptic proteins could explain specific neurological symptoms in patients with encephalitis that are not associated with NMDAR-Abs. The aim of MECANO is to combine multidisciplinary approaches (clinical, immunological, and neurobiological ones) to identify new NSA-Abs, to characterize their specific pathological roles and to decipher acute and chronic NMDAR-Abs effects on biophysical and structural properties of the NMDA receptor, synaptic plasticity, neuronal morphology, and cognitive performance. This project should provide key insights onto the effects of patients' NSA-Abs on the cellular dynamic and regulation of synaptic proteins or receptors and on the molecular cascades activated during synapse dysfunction. The investigators will investigate how NSA-Abs binding alter receptor activity, modify surface receptor mobility and dynamically regulate the maturation of synapses and circuitries. For that purpose, The investigators will use a unique combination of high-resolution imaging (single nanoparticle tracking), receptor engineering, cellular electrophysiology, computational (structural modeling) and cellular and molecular biology approaches and finally behaviour assays. Based on both cutting-edge neurobiology and clinical expertise of autoimmune disorders, and strengthened by promising preliminary experiments, the MECANO project will likely open new avenues of fundamental research in the understanding of synaptic dysfunction and clinical research for the treatment of neuropsychiatric disorders.

Conditions

Autoimmune Encephalitis

Keywords

autoantibodies; neuronal synaptic receptors; autoimmune encephalitis

Outcome Measures

Primary Outcomes (1)

• Pathophysiological study of interaction between specific autoantibodies neuronal synaptic receptors in autoimmune encephalitis : in vivo model

  through study completion, an average of 4 years

Study Arms (1)

Patient with confirmed diagnosis of autoimmune encephalitis by

Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with : * with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr) * or uncharacterized antibodies

Other: Fundamental research

Interventions

Fundamental research OTHER

serum, whole blood, cerebrospinal fluid

Patient with confirmed diagnosis of autoimmune encephalitis by

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with : * with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr) * or uncharacterized antibodies

You may qualify if:

• No age limit
• Diagnosis of autoimmune encephalitis with detection in CSF of characterized antibodies against neuronal synaptic receptor or uncharacterized antibodies
• Written inform consent form
• Affiliated to social security institution
• Availability of surplus biological samples (serum and CSF)

You may not qualify if:

• Other cause of encephalitis (infectious, toxic, metabolic, vascular)
• Impairment of surplus biological samples
• Refusal by the patient

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Institut NeuroMyoGène Équipe Synaptopathies et Autoanticorps (SynatAc) INSERM U1217 / UMR CNRS 5310

Bron, 69500, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum, whole blood, cerebrospinal fluid

MeSH Terms

Conditions

Autoimmune Diseases of the Nervous System

Condition Hierarchy (Ancestors)

Nervous System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Jérôme Honnorat, MD

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 4, 2016
• First Posted: September 19, 2016
• Study Start: May 23, 2017
• Primary Completion: September 30, 2018
• Study Completion: December 3, 2019
• Last Updated: July 29, 2020

Record last verified: 2020-07

Locations

FR (1)